223 related articles for article (PubMed ID: 27055559)
1. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Shitara K; Doi T; Nagano O; Fukutani M; Hasegawa H; Nomura S; Sato A; Kuwata T; Asai K; Einaga Y; Tsuchihashi K; Suina K; Maeda Y; Saya H; Ohtsu A
Gastric Cancer; 2017 Nov; 20(6):1004-1009. PubMed ID: 28466360
[TBL] [Abstract][Full Text] [Related]
3. [Redox regulation in cancer stem cells].
Saya H
Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
[TBL] [Abstract][Full Text] [Related]
4. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Takayama T; Kubo T; Morikawa A; Morita T; Nagano O; Saya H
Med Oncol; 2016 May; 33(5):45. PubMed ID: 27044355
[TBL] [Abstract][Full Text] [Related]
5. Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
Isobe S; Kataoka M; Endo J; Moriyama H; Okazaki S; Tsuchihashi K; Katsumata Y; Yamamoto T; Shirakawa K; Yoshida N; Shimoda M; Chiba T; Masuko T; Hakamata Y; Kobayashi E; Saya H; Fukuda K; Sano M
Am J Respir Cell Mol Biol; 2019 Sep; 61(3):367-379. PubMed ID: 30897333
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
[TBL] [Abstract][Full Text] [Related]
7. Redox regulation in stem-like cancer cells by CD44 variant isoforms.
Nagano O; Okazaki S; Saya H
Oncogene; 2013 Oct; 32(44):5191-8. PubMed ID: 23334333
[TBL] [Abstract][Full Text] [Related]
8. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
[TBL] [Abstract][Full Text] [Related]
9. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
10. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
13. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
15. Combined epithelial-mesenchymal transition with cancer stem cell-like marker as predictors of recurrence after radical resection for gastric cancer.
Xu GF; Zhang WJ; Sun Q; Xu X; Zou X; Guan W
World J Surg Oncol; 2014 Dec; 12():368. PubMed ID: 25441488
[TBL] [Abstract][Full Text] [Related]
16. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.
Wada T; Ishimoto T; Seishima R; Tsuchihashi K; Yoshikawa M; Oshima H; Oshima M; Masuko T; Wright NA; Furuhashi S; Hirashima K; Baba H; Kitagawa Y; Saya H; Nagano O
Cancer Sci; 2013 Oct; 104(10):1323-9. PubMed ID: 23848514
[TBL] [Abstract][Full Text] [Related]
17. [Clinical research of targeting therapy for cancer stem cells].
Shitara K; Doi T
Nihon Rinsho; 2015 May; 73(5):823-30. PubMed ID: 25985638
[TBL] [Abstract][Full Text] [Related]
18. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
[TBL] [Abstract][Full Text] [Related]
19. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
